Myelodysplastic Syndromes (MDS)

Low-Risk MDS

Thumbnail for video Watch Now

Topic(s)
Myelodysplastic Syndromes (MDS)
In this webinar, Dr. Andrew Matthews discusses Low Risk MDS, current treatments and what's on the treatment horizon. Dr. Matthews took many questions from the live audience.

Ashwin Kishtagari, MD

Institution
Vanderbilt University Medical Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)

David Hermel, MD

Institution
Scripps Clinic
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
David Hermel, MD, is a hematologist and medical oncologist who specializes in malignant hematology with an interest in the use of novel therapies, such as cellular immunotherapy and bone marrow transplantation, for the treatment of blood and immune system disorders. As a member of the Scripps Blood and Marrow Transplant Program, he works with a multi-disciplinary team of professionals to provide hematopoietic stem cell transplantation to his patients. Dr. Hermel’s clinical practice is focused on the treatment of blood cancers, such as acute and chronic leukemias, multiple myeloma, Hodgkin’s

Blood Transfusions and Iron Overload

Thumbnail for video Watch Now

Topic(s)
Living Well with Bone Marrow Failure
Managing Your Treatment
In this webinar, Dr. Thomas Coates will discuss blood transfusions and the potential side effect, iron overload. You may submit questions in advance by emailing help@aamds.org.

Toward a more patient-centered drug development process in clinical trials for patients with myelodysplastic syndromes/neoplasms (MDS): Practical considerations from the International Consortium for MDS (icMDS)

Notable treatment advances have been made in recent years for patients with

Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes

Purpose: Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only potentially curative treatment for patients with

Subscribe to Myelodysplastic Syndromes (MDS)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.